7% Hypertonic Saline for Acute Bronchiolitis

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Research suggests that hypertonic saline may improve mucous flow in infants with acute bronchiolitis. Data suggest a trend favoring reduced length of hospital stay and improved pulmonary scores with increasing concentration of nebulized solution to 3% and 5% saline as compared to 0.9% saline mixed with epinephrine. To our knowledge, 7% hypertonic saline has not been previously investigated. OUr hypothesis was that 7% hypertonic saline would improve bronchiolitis severity scores and admission rate.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Le Bonheur Children's Hospital
• Treatments: Epinephrine; Epinephryl borate; Racepinephrine

Criteria

Inclusion Criteria:

• Patients age 6 weeks to ≤ 18 months

• Diagnosed with bronchiolitis (defined as viral respiratory illness and first episode of wheeze)

• BSS score of ≥ 4

Exclusion Criteria:

• A previous history of wheezing;

• diagnosis of asthma;

• any use of bronchodilators within 2 h of presentation

• gestational age ≤ 34 weeks

• history of congenital heart disease

• chronic pulmonary or chronic renal disease

• oxygen saturation of ≤ 85% at the time of recruitment

• severe disease requiring intensive care unit admission

• inability to obtain informed consent